”Lung cancer treatment must be standardized. Pathological examination, staging …… should go through a process that should not be missing, according to the examination results to stage the disease, and then contact the patient’s condition to choose the most suitable treatment plan for them, which is a more standardized way of lung cancer treatment”. According to the pathological type of the disease, the stage, and the patient’s condition, the treatment strategy suitable for the patient is formulated. If the patient is in good health and not an elderly patient, a cisplatin-containing regimen will be recommended; if the patient is older, has more concomitant diseases and is generally in a weaker condition, a carboplatin-containing regimen will be recommended; if some patients cannot even tolerate a carboplatin-containing regimen, a single drug may be recommended to treat the patient. No matter what regimen is used, the premise is: to ensure the patient’s safety and on this basis to achieve a cure of the tumor, or to prolong the patient’s survival and improve the patient’s quality of life. Why is it necessary to perform pathological examination? Patients often say, “The photo found a mass in the lung, doctor, you prescribe a plan and drugs for me. This is definitely not possible. What plan and medicine to be used must be based on the corresponding pathological examination. The diagnosis of lung cancer requires pathological results first. When lung shadows are found, physical discomfort is detected, and the examination reveals an occupying lung mass, there is no way to clearly determine whether it is lung cancer from the perspective of imaging alone. Before puncture, some patients may consider inflammation, but the result is lung cancer; some patients may see lung cancer, but the result is benign disease. With imaging you cannot determine whether the patient is a malignant tumor or not, there must be pathological examination. If a benign disease is treated as a malignant disease, it is unacceptable from my point of view. It is equally unacceptable to the patient and the patient’s family. Moreover, on the basis of pathological examination, corresponding biomarker tests should be done to guide the subsequent individualized treatment. In addition, patients should be staged to understand the extent of tumor lesions, organs involved and whether there are metastases, etc. Staging can directly affect the choice of the best treatment. Lung cancer is usually divided into four stages: IA, IB, IIA, IIB, IIIA, IIIB, and IV. Generally speaking, patients before IIIA can be treated with surgery; IIIB will do simultaneous radiotherapy; stage IV patients will be treated mainly with systemic therapy. Of course, some stage IV patients can also be cured by surgical treatment. With the development of imaging technology, intracranial problems cannot be detected by CT, but if MRI is done, very early and asymptomatic intracranial metastases can be detected, and such patients can be controlled for a long time through treatment. For the stage of lung cancer, there is another treatment method, which is to do induction chemotherapy (i.e. neoadjuvant chemotherapy) first to make the tumor shrink significantly and lower the stage. By this method, all patients who need to have a total lung resection may only need to have a lobectomy, and the degree of impact on patients’ physical damage and quality of life is completely different between the two.